Article
Srsf2P95H/+ co-operates with loss of TET2 to promote myeloid bias and initiate a chronic myelomonocytic leukemia-like disease in mice.
Leukemia - 1 Dec 2022
Xu Jane Jialu, Chalk Alistair M, Wall Meaghan, Langdon Wallace Y, Smeets Monique F, Walkley Carl R
Abstract excerpt
Recurrent mutations in RNA splicing proteins and epigenetic regulators contribute to the development of myelodysplastic syndrome (MDS) and related myeloid neoplasms. In chronic myelomonocytic leukemia (CMML), SRSF2 mutations occur in ~50% of patients and TET2 mutations in ~60%. Clonal analysis indicates that either mutation can arise as the founder lesion. Based on human cancer genetics we crossed an inducible...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.